Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients - Top-Institutions - MDSpire

Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients

  • By

  • Qi Gao

  • Guoxiang Yao

  • Yujiao Sun

  • Xiaoyun Li

  • Zhuo Li

  • Bing Chen

  • June 26, 2026

  • 0 min

Share

Top Institutions in Rheumatology

Brief introduction explaining scope and methodology.

  • #1

    University of British Columbia
    University of British Columbia

    Vancouver, British Columbia

    Key Differentiators

    • Nephrology

  • #2

    British Columbia Cancer Center Agency, Center for Lymphoid Cancer
    British Columbia Cancer Center Agency, Center for Lymphoid Cancer

    Vancouver, British Columbia

    Key Differentiators

    • Oncology

  • #3

    University Hospital Cologne
    University Hospital Cologne

    Cologne, North Rhine-Westphalia

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    German CLL Group
    German CLL Group

    N/A, N/A

    Key Differentiators

    • Hematology

Original Source(s)

Efficacy and safety of obinutuzumab in patients with primary membranous nephropathy: a focus on refractory and rituximab-resistant patients

  • by Qi Gao, Guoxiang Yao, Yujiao Sun, Xiaoyun Li, Zhuo Li, Bing Chen

  • June 26, 2026

Related Content

Patient and physician global assessments capture distinct clinical domains in axial spondyloarthritis

Inflammaging and osteoarthritis - therapeutic opportunities

Is it time for a systematic and objective assessment of knee laxity? The impact of objective knee laxity after TKA on patient-reported outcomes: a comprehensive review